je.st
news
Tag: lillys
This Week In Pharma: Questions On Lilly's Solanezumab Trial Amendments, BioDelivery's BELBUCA
2016-03-22 16:12:08| Biotech - Topix.net
This week's column presents questions on Lilly's solanezumab trial and BELBUCA. Based on your votes for the more interesting topic, Slingshot Insights will interview an expert and post a transcript.
Tags: questions
week
trial
amendments
Drugmaker Lilly's 2016 forecast misses Street expectations
2016-01-05 15:04:53| Biotech - Topix.net
The drugmaker says it expects adjusted earnings in the new year to range between $3.45 and $3.55 per share, excluding charges like deal integration costs. It predicts revenue of between $20.2 billion and $20.7 billion.
Tags: street
expectations
forecast
misses
Drugmaker Lilly's 2016 forecast misses Street expectations
2016-01-05 14:54:31| Food - Topix.net
The drugmaker says it expects adjusted earnings in the new year to range between $3.45 and $3.55 per share, excluding charges like deal integration costs. It predicts revenue of between $20.2 billion and $20.7 billion.
Tags: street
expectations
forecast
misses
Drugmaker Lilly's 2016 forecast misses Street expectations
2016-01-05 14:52:19| Agriculture - Topix.net
The drugmaker says it expects adjusted earnings in the new year to range between $3.45 and $3.55 per share, excluding charges like deal integration costs. It predicts revenue of between $20.2 billion and $20.7 billion.
Tags: street
expectations
forecast
misses
J&J says its diabetes drug should have same survival edge as Lilly's
2015-10-13 19:12:33| Biotech - Topix.net
REUTERS: Johnson & Johnson said the proven ability of Eli Lilly and Co's rival Jardiance diabetes drug to save lives in a large clinical trial is a benefit that will likely be seen in the entire class of drugs, including J&J's own approved Invokana treatment. Dominic Caruso, J&J's chief financial officer, on Tuesday gave his optimistic view of the new drug class, called SGLT2 inhibitors, during a conference call with industry analysts to discuss the company's third-quarter earnings.
Tags: drug
edge
survival
diabetes